







Remarks

In the Official Communication dated 26 March 2008, restriction to one of the following independent and distinct groups of inventions was required:

Group 1	Claims 1,3, 4, 6-13	drawn to: 
Group 2	Claims 1, 3, 4, 6-13	drawn to  not included within Group 1;
Group 3	Claims 1, 3, 4, and 6-13	drawn to  not included within Groups 1 and 2
Group 4	Claims 2, 5, and 30-32	drawn to  , ;
Group 5	Claims 2, 5, and 30-32	drawn to  not included with in Group 2;
Group 6	Claims 2,5, and 30-32	drawn to  not included within Groups 1 and 2;
Group 7	Claims 14-23	drawn to methods using compounds of Group 1;
Group 8	Claims 14-23	drawn to methods using compounds of Group 2;
Group 9	Claims 14-23	drawn to methods using compounds of Group 3;
Group 10	Claims 33-35	drawn to methods using compounds of Group 4;
Group 11	Claims 33-35	drawn to methods using compounds of Group 5;
Group 12	Claims 33-35	drawn to methods using compounds of Group 6.

In response the Applicants elect for substantive examination Group 1, claims 7-9, and 11-13 without traverse. It is noted that claim 3 was included in Groups 1, 2, and 3. However, because of its structure and specifically the attachment of the benzofuranyl ring to the rest of the molecule, it is believed that this claim should instead be included in Groups 4, 5, and 6.

In addition, it was noted that a species selection was not required for Group 1. (Species selection was required for Groups 2-6.)

Status of Claims:

This application was nationalized with claims 1-29. In a Preliminary Amendment claims 24-29 were canceled and new claims 30-35 were added.

In the present Submission, claims 1-6, 10 and 31-35 have been canceled. Claims 7 and 9 have been amended to conform to the election of the Group 1 invention. In addition claim 9 has been amended to include two new compounds exemplified as Examples 7 and 2, respectively. The compounds are included within the scope of the Group 1 invention. Claims 12, 13, 14, 16, and 23 have been amended to depend from new claim 36. Claim 18 has been amended to recite to methods of treating: Acne, Actinic keratosis, Psoriasis, Scleroderma, Skin cancer, Insufficient sebum secretion, Insufficient dermal firmness, Insufficient dermal hydration, Skin cell damage from, Mustard vesicants, Wrinkles and Seborrheic dermatitis. Support for this amendment can be found in original claim 18 and in the application at ¶0021 (published application no. US2007/016095).

New claims 36-39 have been added. Support for claim 36 can be found in the application and in claim 1 as originally filed --amended to conform to the election of the Group 1 invention. New claims 3 and 38 refer to a specific compound exemplified as Example 7. It is believed the amendments do not add new matter.

Claims 36, 37, and 38 claim compounds included within the scope of the Group 1 invention. Claim 39 is drawn to a method of using the compound in claim 37. Therefore, claim 38 would be included within the scope of the invention of Group 7.

Upon allowance of an independent claim to a compound, rejoinder of the method claims of Group 7 will be requested.

The Applicants request timely examination of the elected invention. The Examiner is invited to contact the undersigned attorney by telephone if there are any questions about this Submission or other issues that may be resolved in that fashion.

Respectfully submitted,
/James B. Myers/
James B. Myers
Attorney for Applicants
Registration No. 42,021
Phone: 317-276-0755

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

28 April 2008